CORT Financial Facts

Research and development: 4.25M
Basic and diluted net loss per share: -0.07
See Full Income Statement

Property and equipment , net of accumulated depreciation: 296K
Total liabilities and stockholders' equity: 44.39M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date N/A EPS Growth Rate -10.0% *Last Qtr.
Average EPS % Beat Rate +2.6% Revenue Growth Rate +156.4% *Last Qtr.
Average % Move 1-Wk after EPS -15.9% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/7/14 Q114 -$0.11-$0.09 -$0.02$4.41M$5.01M N/A Details
3/5/14 Q413 -$0.11-$0.10 -$0.01$4.1M$4.01M N/A Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$2.6M$2.7M N/A Details
8/8/13 Q213 -$0.10-$0.11 +$0.01$1.9M$2.72M N/A Details
5/2/13 Q113 -$0.10-$0.09 -$0.01$1.72M$2.48M N/A Details
3/7/13 Q412 -$0.09-$0.09 $0.00$1.38M$1.5M N/A Details
10/31/12 Q312 -$0.08-$0.09 +$0.01$1.05M$2.07M N/A Details
8/7/12 Q212 -$0.09-$0.11 +$0.02N/AN/A N/A Details